Anacor slashes IPO share price; Genzyme meets key deadline on plant decree; Gilead files for approval of combo HIV drug

 @FierceBiotech: Uphill climb gets even steeper for biotech IPOs. Report | Follow @FierceBiotech

 @JohnCFierce: A few weeks ago Amira's Bob Baltera was brimming with confidence about new financing. Today, not so much. Story | Follow @JohnCFierce

> Anacor has priced its IPO, slashing the price and boosting the number of shares on offer as it confronts a chilly reception for classic biotech offerings. Anacor says it will sell 12 million shares at $5 apiece rather than 4.7 million shares for $16 to $18 each. Report

> Genzyme says it met a key component of its consent decree with federal regulators, ending filling and finishing work at the targeted manufacturing facility. Story

Special Report: FierceBiotech's 2010 Fierce 15.  Report

> Gilead filed for regulatory approval of a new combo HIV therapy which matches Truvada with Tibotec's rilpivirine. Story

> Grifols says it has obtained the loans it needs to buy Talecris. Item

Special Report: The Top 10 Phase III Failures of 2010. Report

And Finally... Binghamton University researchers recently revived ancient bacteria trapped for thousands of years in water droplets embedded in salt crystals. Binghamton University release

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.